RESEARKA

What does the current evidence establish about Aspirin Geroprotection and human geroscience? This synthesis tests the thesis that evidence for Aspirin geroprotection is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Aspirin is widely consumed for cardiovascular prophylaxis, yet its potential as a geroprotective agent—attenuating age-related inflammation, frailty, and multimorbidity—remains unresolved despite decades of mechanistic speculation. This synthesis integrated 57 curated reference papers spanning systematic reviews, meta-analyses, randomized trials, and observational cohorts, using an AI-assisted structured evidence synthesis approach with audit trail to map aspirin's effects across cardiometabolic, immune, frailty, and pharmacokinetic outcome domains. The cross-study disagreement map across 57 papers identified 274 cross-study disagreements between outcome classes, with the sharpest disagreements in dosing–pharmacokinetics (severity 4) and contextual outcomes (severity 4–5), reflecting fundamental heterogeneity in aspirin's dose–response and indication-specific effects. While aspirin demonstrates mechanistic plausibility for geroprotection through COX-mediated inflammation resolution and skeletal muscle inflammation hastening following acute injury, the current human evidence—including large randomized trials and cohort studies spanning thousands of participants—do

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Saeed 2026
• source_3 Zhu 2026
• source_4 Navarese 2026
• source_5 Yan 2024